What data sources does EL7.AI use?

EL7.AI uses official data from the Federal Reserve (FOMC), European Central Bank, CFTC (COT reports), BLS, FRED, FMP for prices, and 15+ news sources.

What is the DLS system?

Dictionary-based Linguistic Scoring — a proprietary tone analysis system using a dictionary of 800+ categorized phrases. Reproducible and verifiable results, unlike random AI analysis.

How is EL7.AI different from Bloomberg?

Bloomberg takes years to master and costs $25,000/year. EL7.AI offers the same institutional data with built-in AI analysis at $500/year, with full Arabic support.

What markets are covered?

Stocks from 7 exchanges (NYSE, NASDAQ, LSE, TSE, HKSE, Euronext, XETRA, Tadawul), 28 forex pairs, 300+ cryptocurrencies, 50+ indices, and 40+ commodities.

Is EL7.AI available in Arabic?

Yes! EL7.AI is an Arabic-first platform — everything is available in Arabic with full RTL support: interface, analysis, news, and reports.

How much does EL7.AI cost?

Founding member pricing starts at $500/year (Batch 1). The price is locked forever at this level. Regular pricing will be $1,000/year after official launch.

Is there a refund policy?

Yes — full refund within 7 days of purchase. If you're not satisfied, contact us for a complete refund.

Bank of Japan and Bank of England with DLS, advanced crypto module, enhanced trading signals, and mobile app. All future features are included in your subscription.

Hikma Pharmaceuticals Shares Plunge 16% on Weak 2026 Financial Guidance

Hikma Pharmaceuticals PLC saw its shares tumble by 16% to 1,390p following the release of its latest financial outlook. While the company's 2025 results met analyst expectations, its guidance for 2026 fell significantly short of market forecasts. This disappointing outlook overshadowed the announcement of a share buyback program, triggering a sharp sell-off among investors. Alongside the financial update, the company announced that Executive Chair Said Darwazah will assume the role of full-time CEO for the next two years. Additionally, CFO Khalid Nabilsi has been appointed as Deputy CEO to support the leadership transition. Analysts suggest that the double-digit decline reflects deep investor concern over future growth prospects and the conservative earnings targets provided.

Hikma Pharmaceuticals Shares Plunge 16% on Weak 2026 Financial Guidance

news.keyFacts

news.detail.instrumentsSection

Hikma Pharmaceuticals Shares Plunge 16% on Weak 2026 Financial Guidance

news.keyFacts

news.detail.instrumentsSection